Losigamone add-on therapy for focal epilepsy.

CONCLUSIONS: The results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy. However, the included trials were of short-term duration and uncertain quality. Future well-designed randomized, double-blind, placebo-controlled trials with a longer-term duration are needed. No new studies have been found since the last version of this review. We judged the overall quality of the evidence for the outcomes assessed as moderate. PMID: 29355908 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29355908?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - January 22, 2018 Category: General Medicine Authors: Xiao Y, Luo M, Wang J, Luo H Tags: Cochrane Database Syst Rev Source Type: research